SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksForterra Regulatory News (FORT)

Share Price Information for Forterra (FORT)

Share Price is delayed by 15 minutes
Get Live Data
130.20    2.40 (1.88%)
Bid:
130.00
Ask:
130.40
Spread: 0.40 (0.308%)
Market Cap: £268.15m
FORT Live PriceLast checked at - London Stock Exchange

Intraday Forterra Share Chart

Trading Update

3 Jun 2020 07:00

RNS Number : 7409O
Forterra plc
03 June 2020
 

Forterra plc

 

3 June 2020 

 

 Trading Update

 

Forterra plc, a leading UK producer of manufactured masonry products, provides this update and further detail on the measures it is taking to mitigate the impact of Covid-19.

 

Trading and operational update

 

Since our announcement of 28 April 2020, we have been encouraged by a gradual increase in despatches as our customers reopened their operations. Daily despatches of our brick & block products have now recovered to approximately 50% of corresponding 2019 levels. Group revenue declined by 39% for the five months to 31 May 2020 compared with the corresponding period in 2019, with a year-on-year decline of 86% in April and 62% in May.

 

We are currently manufacturing at twelve of our eighteen facilities and are preparing to further increase production as demand requires. We anticipate recommencing production at most of our remaining facilities by the end of July and retain full flexibility to reopen facilities sooner should demand increase at a faster rate than expected.

 

Restructuring

 

Economic and industry forecasts indicate a prolonged impact from Covid-19 on the UK economy and more specifically the construction sector. Although the Construction Products Association's most recent forecast anticipates the residential construction market will recover during 2021, output in 2021 is forecast to be approximately 20% lower than in 2019.

 

Accordingly, we are taking steps to restructure the Group's operations in line with the anticipated decline in medium-term demand. In the coming weeks we will consult with employees on our plans, which include proposed changes to shift patterns and adjustments to the size and structure of support functions. Additionally, these proposals include consolidating the manufacture of all precast concrete flooring products at our Hoveringham facility in Nottinghamshire. This proposal will necessitate the mothballing of our hollowcore flooring manufacturing facility at Swadlincote in Derbyshire once the current order book is completed. These proposals will not affect our ability to service key customers or our specialist precast concrete facility at Swadlincote. These actions, if implemented, will regrettably lead to the loss of approximately 225 jobs, primarily from our concrete products facilities.

 

Balance sheet and liquidity

The Group entered the Covid-19 crisis with net debt (pre IFRS 16) of £43.2m at 31 December 2019. 

The Group has access to a £150m revolving credit facility which runs to July 2022, which is presently fully drawn. At 31 May 2020 the Group had cash reserves of £79m as well as access to an undrawn overdraft facility of £10m.

In addition, Forterra plc has been confirmed as eligible for the joint HM Treasury and Bank of England Covid Corporate Financing Facility (CCFF) with an issuer limit of £175 million and is now able to access the liquidity available under this facility. The Board does not have any present intention to draw upon this facility, which provides the Group with additional headroom if required.

Summary

Despite the economic circumstances created by Covid-19, the Board remains confident that the Group is well positioned to take advantage of the attractive long-term market fundamentals in order to continue delivering sustainable shareholder value. 

Enquiries:

Forterra plc:

+44 (0) 1604 707 600

Stephen Harrison (CEO) / Ben Guyatt (CFO)

FTI Consulting:

+44 (0) 20 3727 1340

Richard Mountain / Nick Hasell

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) prior to its release as part of this announcement.

Further information relating to the Company and its group can be found at www.forterraplc.co.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBRGDLGBGDGGD
Date   Source Headline
20th Jan 20267:00 amRNSEmployee Benefit Trust Share Purchase
7th Jan 20269:39 amRNSEmployee Benefit Trust Share Purchase
2nd Dec 20259:22 amRNSEmployee Benefit Trust Share Purchase
24th Nov 20259:03 amRNSHolding(s) in Company
20th Nov 20259:13 amRNSHolding(s) in Company
18th Nov 20255:03 pmRNSEmployee Benefit Trust Share Purchase
11th Nov 20257:00 amRNSTrading Update
4th Nov 20254:34 pmRNSEmployee Benefit Trust Share Purchase
24th Oct 20251:36 pmRNSHolding(s) in Company
23rd Oct 20251:21 pmRNSDirector/PDMR Shareholding
17th Oct 20259:58 amRNSEmployee Benefit Trust Share Purchase
14th Oct 20259:06 amRNSHolding(s) in Company
13th Oct 202510:15 amRNSEmployee Benefit Trust Share Purchase
2nd Oct 20252:54 pmRNSGrant of Options under 2025 SAYE Scheme
11th Aug 20251:15 pmRNSHolding(s) in Company
29th Jul 20257:38 amRNS-RProgressive publishes new research
29th Jul 20257:00 amRNSSix months ended 30 June 2025
23rd Jul 202510:05 amRNSHolding(s) in Company
19th Jun 20257:05 amRNSDirector Declaration
20th May 20251:47 pmRNSAnnual General Meeting 2025 Results
20th May 20257:43 amRNS-RProgressive publishes new research
20th May 20257:00 amRNSAGM Trading Update
13th May 202510:36 amRNSHolding(s) in Company
11th Apr 20259:18 amRNSDirector / PCA Shareholdings
2nd Apr 20252:22 pmRNSDirector/PDMR Shareholding
26th Mar 20255:53 pmRNSAnnual Report & Accounts 2024 & Notice of AGM 2025
25th Mar 20251:47 pmRNSDirector/PDMR Shareholding
20th Mar 20252:44 pmRNSHolding(s) in Company
20th Mar 20257:00 amRNSGrant under Performance Share Plan
20th Mar 20257:00 amRNSGrant under Deferred Annual Bonus Plan
18th Mar 20252:23 pmRNSHolding(s) in Company
12th Mar 20258:14 amRNS-RProgressive publishes new research
12th Mar 20257:00 amRNSFull Year Results
6th Mar 20257:00 amRNSAppointment of Independent Non-Executive Director
27th Feb 20253:35 pmRNSHolding(s) in Company
26th Feb 20252:50 pmRNSHolding(s) in Company
4th Feb 20257:00 amRNSDirectorate Change
23rd Jan 20257:00 amRNSFull Year 2024 Trading Update
6th Jan 20259:23 amRNSHolding(s) in Company
2nd Jan 202511:38 amRNSDirector/PDMR Shareholding
11th Nov 20247:00 amRNSTrading update to the end of the October
4th Nov 202410:24 amRNSHolding(s) in Company
30th Oct 20244:54 pmRNSHolding(s) in Company
28th Oct 202411:51 amRNSHolding(s) in Company
2nd Oct 20245:35 pmRNSGrant of Options under 2024 SAYE Scheme
11th Sep 20247:00 amRNSDirectorate Change
5th Sep 202411:49 amRNSHolding(s) in Company
2nd Sep 20249:59 amRNSHolding(s) in Company
12th Aug 20243:03 pmRNSHolding(s) in Company
30th Jul 20247:00 amRNSSix months ended 30 June 2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.